Loading stock data…
GOSS
$0.34+0.01 (+3.58%)
Pre-Market$0.34-0.00 (-0.53%)· Last close May 11
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gossamer Bio, Inc. in the Healthcare sector is trading at $0.34. The stock is currently near its 52-week low of $0.31, remaining 83.2% below its 200-day moving average. Technical signals show neutral RSI of 38 and bullish MACD crossover, explaining why GOSS maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.34
Potential Upside
5%
Whystock Fair Value$0.36
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Hold
Mean target$3.80+1021.9%
Range$0.30 – $15.00
Fundamentals
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$85.12M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
138.78%
Volume
Today's trading volume
2.89M
Recent News
How The Gossamer Bio (GOSS) Story Is Shifting After The PROSERA Miss And Cash Concerns
The latest analyst update keeps Gossamer Bio’s modelled fair value steady at US$3.69, even as some firms cut price targets to around US$0.30 to US$1 following the Phase 3 PROSERA miss and fresh questions about approval odds for seralutinib. Those lower targets reflect concerns around regulatory uncertainty, the overall trial dataset, and the company’s funding needs, while more constructive voices still point to upcoming data and regulatory discussions as possible support. As you read on, you...
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +11.60% and -3.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +29.58% and +193.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How Mixed Trial Results And Balance Sheet Pressure Are Reframing The Gossamer Bio (GOSS) Story
The updated analyst model keeps Gossamer Bio’s Fair Value estimate steady at US$3.69 per share, even as assumptions around growth, profitability and risk shift under the surface. Street commentary links these unchanged targets to a tug of war between mixed seralutinib data, regulatory uncertainty, and balance sheet questions on one side, and a differentiated mechanism with upcoming catalysts on the other. As you read on, you will see how these factors shape the evolving story and what to...
Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback
Gossamer Bio, Inc. (NASDAQ:GOSS) earns a spot on our list of the best penny stocks set to explode. As of April 8, 2026, sentiment around Gossamer Bio, Inc. (NASDAQ:GOSS) remains cautious, with 56% of covering analysts issuing “Hold” ratings on the stock. The consensus price target of $1 implies an upside of 203.31%. Gossamer Bio, […]